RenovoRx Inc. Common Stock (RNXT)
Stock · NASDAQ · Health Care
$1.15as of 10/16/2026
Price chart
Active signals
RNXT Signal Track Record
How signals performed across all stocks →What RNXT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | +3.9% | 51% | August 31, 2026 |
| Bollinger Band Breakout | 22 | -5.3% | 27% | August 28, 2026 |
| Bollinger Band Breakdown | 20 | +3.8% | 55% | October 7, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -3.1% | 36% | July 30, 2026 |
| Any 20-session window (baseline) | -1.0% | 47% |
Computed by MarketWall from daily closing prices since June 10, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headqua…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 17
- Website
- renovorx.com/
Fundamentals
- 1-day range
- $1.14$1.22
- Market cap
- $51.86M
- P/E (trailing)
- —
- P/E (forward)
- -9.50
- EPS (trailing)
- $-0.31
- Dividend yield
- —
- Beta
- 1.07
- Avg. volume
- 797.8K
How RenovoRx Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 30, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
RenovoRx Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RNXTRenovoRx Inc. Common Stock$1.14▼ 4.20%Market cap $51.86MP/E —$0.7006$2.59
- CPHIChina Pharma Holdings Inc. Common Stock$0.71▼ 2.74%Market cap $52.06MP/E —$0.3818$19.19
- SCYXSCYNEXIS Inc. Common Stock$3.67▼ 6.14%Market cap $51.64MP/E —$3.53$9.12
- SDEVStablecoin Development Corporation Common Stock$0.88▼ 13.73%Market cap $52.64MP/E 0.16$0.7809$99.75
- INCRIntercure Ltd. Ordinary Shares$4.57▼ 1.72%Market cap $54.80MP/E —$253.3$2,740
- IBOImpact BioMedical Inc. Common Stock$2.68▼ 15.14%Market cap $48.61MP/E 61.61$4.67$10.47
- TCRTAlaunos Therapeutics Inc. Common Stock$2.63▲ 20.64%Market cap $48.60MP/E —$0.719$4.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RNXT RenovoRx Inc. Common Stock | $51.86M | — | $1.14 | ▼ 4.20% | $0.7006$2.59 |
| CPHI China Pharma Holdings Inc. Common Stock | $52.06M | — | $0.71 | ▼ 2.74% | $0.3818$19.19 |
| SCYX SCYNEXIS Inc. Common Stock | $51.64M | — | $3.67 | ▼ 6.14% | $3.53$9.12 |
| SDEV Stablecoin Development Corporation Common Stock | $52.64M | 0.16 | $0.88 | ▼ 13.73% | $0.7809$99.75 |
| INCR Intercure Ltd. Ordinary Shares | $54.80M | — | $4.57 | ▼ 1.72% | $253.3$2,740 |
| IBO Impact BioMedical Inc. Common Stock | $48.61M | 61.61 | $2.68 | ▼ 15.14% | $4.67$10.47 |
| TCRT Alaunos Therapeutics Inc. Common Stock | $48.60M | — | $2.63 | ▲ 20.64% | $0.719$4.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga · 10/9/2026
- RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Studybenzinga · 10/7/2026
- RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP TrialYahoo · 10/7/2026
- RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP StudyBenzinga · 10/7/2026
- RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic CancerYahoo · 10/1/2026
- RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical CenterBenzinga · 10/1/2026
Insider Activity
Insider Actions →- Macfarlane K. Angela · October 1, 2026 · Grant55.9K
- Laurence Marton · October 1, 2026 · Grant55.9K
- Robert J. Spiegel · October 1, 2026 · Grant55.9K
- Una S. Ryan · October 1, 2026 · Grant55.9K
- Mark Voll · September 10, 2026 · Grant80.0K
- Mark Voll · May 19, 2026 · Buy25.0K @ $0.7876
Institutional Ownership
March 31, 2026
- Total shares held
- 8.41M
- Total value held
- $8.38M
- Institutional holders
- 30
- Unknown3.71M
- Unknown1.67M
- Unknown1.45M
- Unknown381.7K
- Unknown252.5K
- Unknown232.7K
- Unknown99.5K
- Unknown97.2K
- Unknown92.4K
- Unknown63.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
RenovoRx publishes peer-reviewed case series in oncology journal
RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.
RenovoRx publishes peer-reviewed case series in oncology journal. RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.